Fresenius Medical Care Quarter -7.4%: Profit Jump, Cost-Cutting Program, but Outlook Shock

Is the stock drop following the strong Fresenius Medical Care quarter an overreaction or a warning signal for 2026?

Fresenius Medical Care Quarter: How Strong Was the Profit Surge?

Fresenius Medical Care AG delivered a truly milestone year in 2025. The adjusted operating profit climbed by 23% to €2.21 billion, even 27% when adjusted for currency. In the fourth quarter of Fresenius Medical Care, the momentum accelerated significantly: the adjusted operating profit jumped by 44% to €705 million, clearly exceeding market expectations. The operating margin rose to 13.9%, up from 9.6% in the previous year, placing it at the upper end of the medium-term target range.

Even the bottom line looks significantly better: the net profit surged by 82% to €978 million in 2025. The reported operating profit increased by 31% to €1.83 billion. Group revenue rose by 2% to €19.63 billion; at constant exchange rates, this corresponds to an increase of about 5%. Earnings per share nominally increased by 83% to €3.36, adjusted to €4.28 – a growth of 39%.

CEO Helen Giza described it as a “milestone year with outstanding profitability increases” and emphasized that the company has significantly strengthened its financial foundation over the past three years. With this, Fresenius Medical Care has temporarily shed its reputation as a former DAX problem child.

Fresenius Medical Care: What Does the FME25+ Cost-Cutting Program Bring?

A key driver of the strong numbers in the Fresenius Medical Care quarter is the efficiency program FME25+. In 2025, savings of €238 million were realized, surpassing the original target of €220 million. Management is tightening the reins further: by the end of 2027, a cumulative €1.2 billion is to be saved. This strict cost discipline has significantly contributed to raising the operating margin to 11.3% for the entire year.

Shareholders benefit from the success: the dividend for 2025 is set to increase by five cents to €1.49 per share. This corresponds to a payout ratio of about one-third of the adjusted group profit. Additionally, a share buyback program totaling €1 billion is underway. The first tranche of nearly €600 million was completed at the end of 2025; 14.1 million shares were repurchased. The second tranche of approximately €414 million has been running since January 2026 and is expected to be completed by May.

This underscores management’s confidence in its own course – even if the market reacts differently today. In the medium to long term, Fresenius Medical Care aims for an average annual growth of operating profit of 3% to 7% by 2028 and a leading industry operating margin in the mid-teens percentage range by 2030.

Fresenius Medical Care AG (FME.DE) Stock Chart — 1-Year Chart · Source: stocknewsroom.com

Fresenius Medical Care: Why Is the 2026 Outlook a Drag?

Despite the strong Fresenius Medical Care quarter, the stock market reacted coolly to the new figures. The current stock price is around €38.33, which is about 7% below the Xetra closing price of €41.39 from the previous day. This further distances the value from the 52-week high of about €54 and moves it toward the annual low of just under €36 – the stock is far from new highs.

The trigger for the disappointment is the cautious outlook for 2026. Fresenius Medical Care expects revenue, adjusted for currency, to remain at last year’s level. Regarding the adjusted operating profit, CEO Helen Giza only anticipates a range between a slight decline and a slight increase in the low single-digit percentage range. The background is primarily costs related to the launch of a new dialysis device in the U.S., which will temporarily pressure profitability.

Analysts are responding cautiously: Jefferies analyst James Vane-Tempest notes that the “largely stable outlook” is likely to disappoint and points to increasing headwinds for operating profit. JPMorgan expert David Adlington emphasizes that no profit increase is expected in 2026 and maintains an “Underweight” rating with his skeptical assessment, while Jefferies continues to rate the stock as “Underperform.” This further weighs on the sentiment surrounding the current Fresenius Medical Care quarter.

Fresenius Medical Care has concluded a milestone year with outstanding profitability increases.
— Helen Giza, CEO of Fresenius Medical Care

Bottom Line

For investors, the tension between a strong past Fresenius Medical Care quarter, a consistent cost-cutting program, and a muted outlook suggests that the focus is likely to shift more toward the medium-term story. It will be crucial whether the introduction of the new dialysis device and the expansion of FME25+ starting in 2027 can lead to more sustainable profit growth.